Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 40 min ago
Peer-reviewedCC BY-NC-NDActa pharmaceutica Sinica. B

Concurrent loss of RB1 facilitates EGFR-TKI resistance in EGFR-mutant lung cancer by modulating histone crotonylation

4 affiliations
  1. 1Benxi Institute of Pharmaceutical Research, Shenyang Pharmaceutical University, Shenyang 110016, China
  2. 2Department of Thoracic Surgery, Chest Hospital of Shenyang Pharmaceutical University, Shenyang 110044, China
  3. 3Department of Thoracic Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China
  4. 4Department of Pharmacy, Shengjing Hospital of China Medical University, Shenyang 110004, China

Abstract

Lung cancer harboring epidermal growth factor receptor (EGFR) mutations exhibits marked heterogeneity in clinical responses to EGFR tyrosine kinase inhibitors (EGFR-TKIs), indicating that co-occurring genetic alterations critically influence therapeutic outcomes. However, the underlying mechanisms remain incompletely understood. Here, we modeled frequent EGFR co-alterations using CRISPR-mediated gene knockout and Tet-On-based gene overexpression in two EGFR-mutant cell lines. Functional screening across cell lines and patient-derived organoids revealed that concurrent loss of retinoblastoma 1 (RB1) significantly reduced sensitivity to EGFR-TKIs. Integrated transcriptomic and metabolomic analyses further demonstrated that RB1 deficiency induced extensive metabolic reprogramming, leading to decreased intracellular crotonyl-CoA levels and reduced histone crotonylation. Among multiple crotonylation sites, histone H3 lysine 23 crotonylation (H3K23cr) emerged as a critical determinant of EGFR-TKI responsiveness. Mechanistically, decreased H3K23cr was associated with transcriptional repression of PEBP1 and reduced expression of the PEBP1-encoded Raf kinase inhibitor protein (RKIP), thereby sustaining RAF/MEK/ERK pathway activation and attenuating EGFR-TKI efficacy. Importantly, pharmacological restoration of histone crotonylation or inhibition of MAPK signaling effectively resensitized EGFR/RB1 co-mutant models to EGFR-TKIs. Taken together, our findings identify a metabolic-epigenetic mechanism linking RB1 loss to reduced histone crotonylation and EGFR-TKI resistance, highlighting therapeutically actionable vulnerabilities in EGFR/RB1 co-mutant lung cancer.

Related

  1. PADI2 facilitates progression and cisplatin resistance of epithelial ovarian cancer via m6A methylation
    Xinming Yin, Jiamin Zhou, Shijie Zhao +9
    iSciencePeer-reviewedCC BY-NC-ND 4.0Molecular biology & gene regulationCell biologyCell PressCrossref
  2. IPO5 contributes to cetuximab resistance in colorectal cancer by modulating Ras signaling
    Qinzi Yuan, Siqi Lu, Xiaoxi He +7
    iSciencePeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossrefEurope PMC
  3. Non-histone protein L-lactylation in cancer: a metabolic switch for immune evasion and therapeutic resistance.
    Yingli Guo, Lanyang Gao, Shunda Li +3
    Molecular cancerPeer-reviewedCC BYFull text1 citedOncologyEurope PMCPMC
  4. A Duplex Isothermal RPA–Lateral Flow Platform for Concurrent Detection of Staphylococcus Aureus and mecA-Mediated Methicillin Resistance
    Jutturong Ckumdee, Somchai Santiwatanakul, Kwanchai Onruang +1
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMCDOAJ
  5. Exploratory serum renal biomarker and eGFR responses to high-protein diets during resistance versus concurrent training in resistance-trained men
    Reza Bagheri, Zohreh Karimi, Hamid Ghobadi +7
    Journal of the International Society of Sports NutritionPeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMC
BibTeX
@article{chen2026concurrent,
  title = {{Concurrent loss of RB1 facilitates EGFR-TKI resistance in EGFR-mutant lung cancer by modulating histone crotonylation}},
  author = {Sihong Chen and Xiaoyuan Wang and Qihao Xuan and Chang Liu and Youwei Su and Zongang Liu and Lina Jia and Yi Ren and Wei Cui and Xinyu Fan and Lihui Wang},
  journal = {Acta pharmaceutica Sinica. B},
  year = {2026},
  month = aug,
  doi = {10.1016/j.apsb.2026.08.007},
  url = {https://europepmc.org/article/PMC/PMC13730233},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Concurrent loss of RB1 facilitates EGFR-TKI resistance in EGFR-mutant lung cancer by modulating histone crotonylation
AU  - Sihong Chen
AU  - Xiaoyuan Wang
AU  - Qihao Xuan
AU  - Chang Liu
AU  - Youwei Su
AU  - Zongang Liu
AU  - Lina Jia
AU  - Yi Ren
AU  - Wei Cui
AU  - Xinyu Fan
AU  - Lihui Wang
PY  - 2026
DA  - 2026/08/08
JO  - Acta pharmaceutica Sinica. B
DO  - 10.1016/j.apsb.2026.08.007
UR  - https://europepmc.org/article/PMC/PMC13730233
AB  - Lung cancer harboring epidermal growth factor receptor (EGFR) mutations exhibits marked heterogeneity in clinical responses to EGFR tyrosine kinase inhibitors (EGFR-TKIs), indicating that co-occurring genetic alterations critically influence therapeutic outcomes. However, the underlying mechanisms remain incompletely understood. Here, we modeled frequent EGFR co-alterations using CRISPR-mediated gene knockout and Tet-On-based gene overexpression in two EGFR-mutant cell lines. Functional screening across cell lines and patient-derived organoids revealed that concurrent loss of retinoblastoma 1 (RB1) significantly reduced sensitivity to EGFR-TKIs. Integrated transcriptomic and metabolomic analyses further demonstrated that RB1 deficiency induced extensive metabolic reprogramming, leading to decreased intracellular crotonyl-CoA levels and reduced histone crotonylation. Among multiple crotonylation sites, histone H3 lysine 23 crotonylation (H3K23cr) emerged as a critical determinant of EGFR-TKI responsiveness. Mechanistically, decreased H3K23cr was associated with transcriptional repression of PEBP1 and reduced expression of the PEBP1-encoded Raf kinase inhibitor protein (RKIP), thereby sustaining RAF/MEK/ERK pathway activation and attenuating EGFR-TKI efficacy. Importantly, pharmacological restoration of histone crotonylation or inhibition of MAPK signaling effectively resensitized EGFR/RB1 co-mutant models to EGFR-TKIs. Taken together, our findings identify a metabolic-epigenetic mechanism linking RB1 loss to reduced histone crotonylation and EGFR-TKI resistance, highlighting therapeutically actionable vulnerabilities in EGFR/RB1 co-mutant lung cancer.
SN  - 2211-3835
SN  - 2211-3843
ER  -